| Dr Christine Boehringer, DO | |
|
500 Walter St Ne, Ste 104, Albuquerque, NM 87102-2534 | |
| (505) 848-3730 | |
| Not Available |
| Full Name | Dr Christine Boehringer |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 29 Years |
| Location | 500 Walter St Ne, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376545848 | NPI | - | NPPES |
| 00AX70010 | Medicaid | NM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | A-1556-10 (New Mexico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| San Juan Regional Medical Center | Farmington, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Access Telecare Pllc | 7810204831 | 262 |
| San Juan Regional Medical Center, Inc. | 4587559505 | 177 |
News Archive
This research was developed by Dr. Enrique Garcia Artero, from the Department of Physiology of the University of Granada, and coordinated by Professor Manuel J. Castillo Garzón. To carry out this project, the researcher used data from the national and European projects AVENA (Food and Assessment of Nutritional Status of Spanish Adolescents) and HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence) and ALPHA (Assessing Levels of Physical Activity and Fitness; Public Health Executive Agency).
Hospira, Inc., a global specialty pharmaceutical and medication delivery company, and Javelin Pharmaceuticals, Inc., today announced that the companies have entered into a definitive merger agreement providing for the acquisition of Javelin by Hospira for $2.20 per share in cash, or approximately $145 million. Hospira expects to commence a tender offer for all outstanding shares of Javelin common stock on or about April 21, 2010, in accordance with the terms of the merger agreement.
Researchers who analyzed data for São Paulo state, Brazil, found the highest rates of newborn mortality from asphyxia in cities in the south, southeast and north of the state between 2004 and 2013.
ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.
Aging black men are at much greater risk of dying prematurely of colorectal cancer than any other group in the United States, and are less likely than their white counterparts to be diagnosed at an early stage of the disease.
› Verified 7 days ago
| Entity Name | Southwest Medical Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164491072 PECOS PAC ID: 7214831114 Enrollment ID: O20031121000724 |
News Archive
This research was developed by Dr. Enrique Garcia Artero, from the Department of Physiology of the University of Granada, and coordinated by Professor Manuel J. Castillo Garzón. To carry out this project, the researcher used data from the national and European projects AVENA (Food and Assessment of Nutritional Status of Spanish Adolescents) and HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence) and ALPHA (Assessing Levels of Physical Activity and Fitness; Public Health Executive Agency).
Hospira, Inc., a global specialty pharmaceutical and medication delivery company, and Javelin Pharmaceuticals, Inc., today announced that the companies have entered into a definitive merger agreement providing for the acquisition of Javelin by Hospira for $2.20 per share in cash, or approximately $145 million. Hospira expects to commence a tender offer for all outstanding shares of Javelin common stock on or about April 21, 2010, in accordance with the terms of the merger agreement.
Researchers who analyzed data for São Paulo state, Brazil, found the highest rates of newborn mortality from asphyxia in cities in the south, southeast and north of the state between 2004 and 2013.
ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.
Aging black men are at much greater risk of dying prematurely of colorectal cancer than any other group in the United States, and are less likely than their white counterparts to be diagnosed at an early stage of the disease.
› Verified 7 days ago
| Entity Name | San Juan Regional Medical Center, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639662901 PECOS PAC ID: 4587559505 Enrollment ID: O20040218000865 |
News Archive
This research was developed by Dr. Enrique Garcia Artero, from the Department of Physiology of the University of Granada, and coordinated by Professor Manuel J. Castillo Garzón. To carry out this project, the researcher used data from the national and European projects AVENA (Food and Assessment of Nutritional Status of Spanish Adolescents) and HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence) and ALPHA (Assessing Levels of Physical Activity and Fitness; Public Health Executive Agency).
Hospira, Inc., a global specialty pharmaceutical and medication delivery company, and Javelin Pharmaceuticals, Inc., today announced that the companies have entered into a definitive merger agreement providing for the acquisition of Javelin by Hospira for $2.20 per share in cash, or approximately $145 million. Hospira expects to commence a tender offer for all outstanding shares of Javelin common stock on or about April 21, 2010, in accordance with the terms of the merger agreement.
Researchers who analyzed data for São Paulo state, Brazil, found the highest rates of newborn mortality from asphyxia in cities in the south, southeast and north of the state between 2004 and 2013.
ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.
Aging black men are at much greater risk of dying prematurely of colorectal cancer than any other group in the United States, and are less likely than their white counterparts to be diagnosed at an early stage of the disease.
› Verified 7 days ago
| Entity Name | Infectious Diseases And Internal Medicine Associates P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932275021 PECOS PAC ID: 4183617913 Enrollment ID: O20040406001719 |
News Archive
This research was developed by Dr. Enrique Garcia Artero, from the Department of Physiology of the University of Granada, and coordinated by Professor Manuel J. Castillo Garzón. To carry out this project, the researcher used data from the national and European projects AVENA (Food and Assessment of Nutritional Status of Spanish Adolescents) and HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence) and ALPHA (Assessing Levels of Physical Activity and Fitness; Public Health Executive Agency).
Hospira, Inc., a global specialty pharmaceutical and medication delivery company, and Javelin Pharmaceuticals, Inc., today announced that the companies have entered into a definitive merger agreement providing for the acquisition of Javelin by Hospira for $2.20 per share in cash, or approximately $145 million. Hospira expects to commence a tender offer for all outstanding shares of Javelin common stock on or about April 21, 2010, in accordance with the terms of the merger agreement.
Researchers who analyzed data for São Paulo state, Brazil, found the highest rates of newborn mortality from asphyxia in cities in the south, southeast and north of the state between 2004 and 2013.
ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.
Aging black men are at much greater risk of dying prematurely of colorectal cancer than any other group in the United States, and are less likely than their white counterparts to be diagnosed at an early stage of the disease.
› Verified 7 days ago
| Entity Name | Signify Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689158487 PECOS PAC ID: 3274895263 Enrollment ID: O20210512001500 |
News Archive
This research was developed by Dr. Enrique Garcia Artero, from the Department of Physiology of the University of Granada, and coordinated by Professor Manuel J. Castillo Garzón. To carry out this project, the researcher used data from the national and European projects AVENA (Food and Assessment of Nutritional Status of Spanish Adolescents) and HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence) and ALPHA (Assessing Levels of Physical Activity and Fitness; Public Health Executive Agency).
Hospira, Inc., a global specialty pharmaceutical and medication delivery company, and Javelin Pharmaceuticals, Inc., today announced that the companies have entered into a definitive merger agreement providing for the acquisition of Javelin by Hospira for $2.20 per share in cash, or approximately $145 million. Hospira expects to commence a tender offer for all outstanding shares of Javelin common stock on or about April 21, 2010, in accordance with the terms of the merger agreement.
Researchers who analyzed data for São Paulo state, Brazil, found the highest rates of newborn mortality from asphyxia in cities in the south, southeast and north of the state between 2004 and 2013.
ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.
Aging black men are at much greater risk of dying prematurely of colorectal cancer than any other group in the United States, and are less likely than their white counterparts to be diagnosed at an early stage of the disease.
› Verified 7 days ago
| Entity Name | Access Telecare Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013303080 PECOS PAC ID: 7810204831 Enrollment ID: O20211007003008 |
News Archive
This research was developed by Dr. Enrique Garcia Artero, from the Department of Physiology of the University of Granada, and coordinated by Professor Manuel J. Castillo Garzón. To carry out this project, the researcher used data from the national and European projects AVENA (Food and Assessment of Nutritional Status of Spanish Adolescents) and HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence) and ALPHA (Assessing Levels of Physical Activity and Fitness; Public Health Executive Agency).
Hospira, Inc., a global specialty pharmaceutical and medication delivery company, and Javelin Pharmaceuticals, Inc., today announced that the companies have entered into a definitive merger agreement providing for the acquisition of Javelin by Hospira for $2.20 per share in cash, or approximately $145 million. Hospira expects to commence a tender offer for all outstanding shares of Javelin common stock on or about April 21, 2010, in accordance with the terms of the merger agreement.
Researchers who analyzed data for São Paulo state, Brazil, found the highest rates of newborn mortality from asphyxia in cities in the south, southeast and north of the state between 2004 and 2013.
ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.
Aging black men are at much greater risk of dying prematurely of colorectal cancer than any other group in the United States, and are less likely than their white counterparts to be diagnosed at an early stage of the disease.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christine Boehringer, DO 500 Walter St Ne, Ste 104, Albuquerque, NM 87102-2534 Ph: (505) 848-3730 | Dr Christine Boehringer, DO 500 Walter St Ne, Ste 104, Albuquerque, NM 87102-2534 Ph: (505) 848-3730 |
News Archive
This research was developed by Dr. Enrique Garcia Artero, from the Department of Physiology of the University of Granada, and coordinated by Professor Manuel J. Castillo Garzón. To carry out this project, the researcher used data from the national and European projects AVENA (Food and Assessment of Nutritional Status of Spanish Adolescents) and HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence) and ALPHA (Assessing Levels of Physical Activity and Fitness; Public Health Executive Agency).
Hospira, Inc., a global specialty pharmaceutical and medication delivery company, and Javelin Pharmaceuticals, Inc., today announced that the companies have entered into a definitive merger agreement providing for the acquisition of Javelin by Hospira for $2.20 per share in cash, or approximately $145 million. Hospira expects to commence a tender offer for all outstanding shares of Javelin common stock on or about April 21, 2010, in accordance with the terms of the merger agreement.
Researchers who analyzed data for São Paulo state, Brazil, found the highest rates of newborn mortality from asphyxia in cities in the south, southeast and north of the state between 2004 and 2013.
ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.
Aging black men are at much greater risk of dying prematurely of colorectal cancer than any other group in the United States, and are less likely than their white counterparts to be diagnosed at an early stage of the disease.
› Verified 7 days ago
Dr. Alberto Aguayo Rico, M.D, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 401 San Mateo Blvd Se, Albuquerque, NM 87108 Phone: 505-462-7333 Fax: 505-462-7440 | |
Peter Guido, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 4700 Jefferson St Ne, Ste 800, Albuquerque, NM 87109 Phone: 505-872-6000 Fax: 505-872-6003 | |
Kenneth A Bell, DO Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2901 Transport St Se, Albuquerque, NM 87106 Phone: 505-262-7110 Fax: 505-262-7308 | |
Joseph F. Oser, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 1501 San Pedro Dr Se, Albuquerque, NM 87108 Phone: 505-265-1711 | |
Dr. Stanley Zissman Berman, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 7416 Vista Del Arroyo Ave Ne, Albuquerque, NM 87109 Phone: 505-884-7270 | |
Huyentrang Vu, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: Unm Hospital Internal Medicine, 2211 Lomas Blvd Ne, Albuquerque, NM 87131 Phone: 505-272-6225 | |
Tamara Goodman, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 4901 Lang Ave Ne, Albuquerque, NM 87109 Phone: 505-842-8171 |